Joshua Liang, Clover Biopharmaceuticals CEO
January 5, 2022 10:28 AM ESTUpdated 10:48 AM
R&D
China
Manufacturing

Clover Bio­phar­ma­ceu­ti­cals sets up a new R&D cen­ter in a buzzy Chi­nese hub near Shang­hai

Nicole DeFeudis

Editor

Busi­ness in Chi­na is boom­ing, with more than a thou­sand biotech and bio­phar­ma com­pa­nies — in­clud­ing some big multi­na­tion­al play­ers — flock­ing to Zhangjiang Phar­ma Val­ley …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times